Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the GSK HPV-023 Study [EXTENSION OF 700015423]

Trial Profile

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the GSK HPV-023 Study [EXTENSION OF 700015423]

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Jan 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 06 Mar 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
    • 06 Sep 2013 Planned end date changed from 1 Apr 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top